RB1-Negative Retinal Organoids Display Proliferation of Cone Photoreceptors and Loss of Retinal Differentiation
- PMID: 35565295
- PMCID: PMC9105736
- DOI: 10.3390/cancers14092166
RB1-Negative Retinal Organoids Display Proliferation of Cone Photoreceptors and Loss of Retinal Differentiation
Abstract
Retinoblastoma is a tumor of the eye in children under the age of five caused by biallelic inactivation of the RB1 tumor suppressor gene in maturing retinal cells. Cancer models are essential for understanding tumor development and in preclinical research. Because of the complex organization of the human retina, such models were challenging to develop for retinoblastoma. Here, we present an organoid model based on differentiation of human embryonic stem cells into neural retina after inactivation of RB1 by CRISPR/Cas9 mutagenesis. Wildtype and RB1 heterozygous mutant retinal organoids were indistinguishable with respect to morphology, temporal development of retinal cell types and global mRNA expression. However, loss of pRB resulted in spatially disorganized organoids and aberrant differentiation, indicated by disintegration of organoids beyond day 130 of differentiation and depletion of most retinal cell types. Only cone photoreceptors were abundant and continued to proliferate, supporting these as candidate cells-of-origin for retinoblastoma. Transcriptome analysis of RB1 knockout organoids and primary retinoblastoma revealed gain of a retinoblastoma expression signature in the organoids, characterized by upregulation of RBL1 (p107), MDM2, DEK, SYK and HELLS. In addition, genes related to immune response and extracellular matrix were specifically upregulated in RB1-negative organoids. In vitro retinal organoids therefore display some features associated with retinoblastoma and, so far, represent the only valid human cancer model for the development of this disease.
Keywords: RNA-seq; retinal organoids; retinoblastoma; stem cells.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures







Similar articles
-
Heterozygous RB1 mutation enhanced ATP production in human iPSC-derived retinal organoids.Mol Biol Rep. 2024 May 5;51(1):606. doi: 10.1007/s11033-024-09564-9. Mol Biol Rep. 2024. PMID: 38704498
-
Role of RB1 in human embryonic stem cell-derived retinal organoids.Dev Biol. 2020 Jun 15;462(2):197-207. doi: 10.1016/j.ydbio.2020.03.011. Epub 2020 Mar 19. Dev Biol. 2020. PMID: 32197890 Free PMC article.
-
pRB-Depleted Pluripotent Stem Cell Retinal Organoids Recapitulate Cell State Transitions of Retinoblastoma Development and Suggest an Important Role for pRB in Retinal Cell Differentiation.Stem Cells Transl Med. 2022 Apr 29;11(4):415-433. doi: 10.1093/stcltm/szac008. Stem Cells Transl Med. 2022. PMID: 35325233 Free PMC article.
-
RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis.J Cell Physiol. 2013 Aug;228(8):1676-87. doi: 10.1002/jcp.24329. J Cell Physiol. 2013. PMID: 23359405 Review.
-
Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation.Crit Rev Biochem Mol Biol. 1996 Jun;31(3):237-71. doi: 10.3109/10409239609106585. Crit Rev Biochem Mol Biol. 1996. PMID: 8817077 Review.
Cited by
-
Application of Human Stem Cell Derived Retinal Organoids in the Exploration of the Mechanisms of Early Retinal Development.Stem Cell Rev Rep. 2023 Aug;19(6):1755-1772. doi: 10.1007/s12015-023-10553-x. Epub 2023 Jun 3. Stem Cell Rev Rep. 2023. PMID: 37269529 Review.
-
Retinal Organoids from Induced Pluripotent Stem Cells of Patients with Inherited Retinal Diseases: A Systematic Review.Stem Cell Rev Rep. 2025 Jan;21(1):167-197. doi: 10.1007/s12015-024-10802-7. Epub 2024 Oct 18. Stem Cell Rev Rep. 2025. PMID: 39422807 Free PMC article.
-
Sunitinib efficacy with minimal toxicity in patient-derived retinoblastoma organoids.J Exp Clin Cancer Res. 2023 Feb 1;42(1):39. doi: 10.1186/s13046-023-02608-1. J Exp Clin Cancer Res. 2023. PMID: 36726110 Free PMC article.
-
Human Retinal Organoids in Therapeutic Discovery: A Review of Applications.Handb Exp Pharmacol. 2023;281:157-187. doi: 10.1007/164_2023_691. Handb Exp Pharmacol. 2023. PMID: 37608005 Free PMC article. Review.
-
Heterozygous RB1 mutation enhanced ATP production in human iPSC-derived retinal organoids.Mol Biol Rep. 2024 May 5;51(1):606. doi: 10.1007/s11033-024-09564-9. Mol Biol Rep. 2024. PMID: 38704498
References
-
- Kooi I.E., Mol B.M., Massink M.P., Ameziane N., Meijers-Heijboer H., Dommering C.J., van Mil S.E., de Vries Y., van der Hout A.H., Kaspers G.J., et al. Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes. Sci. Rep. 2016;6:25264. doi: 10.1038/srep25264. - DOI - PMC - PubMed
-
- Rushlow D.E., Mol B.M., Kennett J.Y., Yee S., Pajovic S., Thériault B.L., Prigoda-Lee N.L., Spencer C., Dimaras H., Corson T.W., et al. Characterisation of retinoblastomas without RB1 mutations: Genomic, gene expression, and clinical studies. Lancet Oncol. 2013;14:327–334. doi: 10.1016/S1470-2045(13)70045-7. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous